Ernexa Therapeutics Inc. has announced a change in its independent registered public accounting firm, dismissing Grant Thornton LLP effective June 30, 2025, and appointing Haskell & White LLP on July 1, 2025. This decision was approved by the Audit Committee of Ernexa's Board of Directors. The company reported no disagreements or reportable events with Grant Thornton during the two years ending December 31, 2024, and the interim period through June 30, 2025, except for a noted material weakness in Ernexa's internal control over financial reporting for the year ending December 31, 2023, due to insufficient technical accounting proficiency in complex matters. Prior to the appointment, Ernexa had not consulted Haskell & White regarding any accounting principles or audit opinions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.